Apexigen partners with and licenses its programs and intellectual property to biotechnology and pharmaceutical companies and other entities to meet our strategic objectives. We have partnered with and licensed certain of our intellectual property to certain of the entities identified below to advance our programs and technology and facilitate clinical research of our drug candidates to advance the treatment of patients with cancer.

columbia logo

mabwell logo 

md andersen cancer center logo 

nsgo-ctu logo 

oculis logo

parker institute logo

simcere logo

toray logo

yale logo


Apexigen is interested in

  • Strategic collaborations and out-licenses of rights to advance the discovery and development of innovative oncology drugs
  • In-license and co-development opportunities for oncology therapeutics

Apexigen welcomes inquiries from companies interested in partnering and licensing relationships. Contact us at